门诊中成药处方重复用药情况分析与前置审方规则建立OA
Analysis of duplicate medication use in outpatient prescriptions of Chinese patent medicines and development of pre-prescription review rules
目的 发现中成药重复使用问题,建立精细化审方规则,优化审核标准以提升用药合理性与安全性.方法 抽取2025年1月1日至4月30日医院门诊处方中品种数量≥2种的中成药联用处方5 000张,依据中成药重复用药评分标准表评分、划分风险等级,建立前置审方规则,实施用药干预.结果 5 000张中成药联用处方中,710张(占14.2%)存在重复用药,涉及30种不同风险等级药物联用,其中高风险17种(共468例,含肛泰栓联合肛泰软膏196例、复方丹参滴丸联合速效救心丸105例等),中风险6种(共159例),低风险7种(共83例).据此制定28项审方规则,包含"警示提醒+系统拦截"15项、"警示提醒+医师双签确认"6项和"警示提醒+系统通过"7项.结论 该院门诊中成药重复用药较为普遍,且不乏高风险情况.为降低用药安全隐患,建议通过信息化系统实施前置审方干预.
AIM To identify the problem of duplicate medication use of Chinese patent medicines,establish refined prescription review rules,and optimize review standards to improve the rationality and safety of medication use.METHODS A total of 5 000 prescriptions for the combined use of two or more kinds of Chinese patent medicines were selected from the outpatient prescriptions from January 1 to April 30,2025.The prescriptions were scored and classified into risk levels according to the scoring criteria for duplicate medication use of Chinese patent medicines,and pre-prescription review rules were established accordingly to implement medication intervention.RESULTS Of the 5 000 prescriptions with combined use of Chinese patent medicines,710(14.2%)involved duplicate medication use,covering 30 drug combinations of various risk levels.Among them,there were 17 high-risk combinations(468 cases,including 196 cases of Gangtai Suppository combined with Gangtai Ointment and 105 cases of Compound Danshen Dripping Pills combined with Suxiao Jiuxin Pills),6 medium-risk combinations(159 cases),and 7 low-risk combinations(83 cases).Based on these findings,28 prescription review rules were formulated,including 15 rules of"warning reminder+system interception",6 rules of"warning reminder+physician double-signature confirmation",and 7 rules of"waming reminder+system approval".CONCLUSION Duplicate medication use of Chinese patent medicines in outpatient settings of this hospital is relatively common,including high-risk cases.To reduce potential medication safety hazards,it is necessary to implement a prospective prescription review intervention through an information system.
朱玲娜;汪龙;郭红叶;程军;年士恒;徐智娟
蚌埠市第三人民医院药学部,蚌埠 233099蚌埠市第三人民医院药学部,蚌埠 233099中国中医科学院西苑医院药学部,北京 100091蚌埠市第三人民医院药学部,蚌埠 233099蚌埠市第三人民医院药学部,蚌埠 233099蚌埠市第三人民医院中西医结合科,蚌埠 233099
医药卫生
中成药重复用药处方点评处方前置审核审核规则
Chinese patent medicineduplicate medication useprescription reviewpre-prescription reviewreview rules
《中国临床药学杂志》 2026 (8)
699-704,6
"卫健联盟"成员单位及非直属附属医院2025年度蚌埠医科大学科技项目(编号2025byzd292sk)2024年度蚌埠市科技创新指导类项目(编号2024ZD0050)
评论